首页> 外国专利> FUSION PROTEIN USED FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

FUSION PROTEIN USED FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

机译:用于预防和治疗老年痴呆症的融合蛋白,其制备方法及其应用

摘要

A fusion protein used for preventing and treating Alzheimer's disease, a preparation method therefor, and an application thereof. The fusion protein comprises the extracellular domain of human p75NTR human IL-33 and a linker peptide respectively connected to the carboxyl terminus of the p75NTR-ECD and the amino terminus of the human IL-33. The amino acid sequence of the p75NTR-ECD is as shown in SEQ ID NO: 1, and the nucleotide sequence is as shown in SEQ ID NO: 2. The amino acid sequence of the human IL-33 is as shown in SEQ ID NO: 3, and the nucleotide sequence is as shown in SEQ ID NO. 4. The invention overcomes the defects of the p75NTR-ECD or a fusion protein p75NTR-ECD-FC), for preventing and treating Alzheimer's disease. In addition, the functions of the IL-33 and the p75NTR-ECD are combined together, and the biological activity for preventing and treating Alzheimer's disease is significantly increased.
机译:用于预防和治疗阿尔茨海默氏病的融合蛋白,其制备方法及其应用。融合蛋白包含人p75NTR人IL-33的胞外结构域和分别与p75NTR-ECD的羧基末端和人IL-33的氨基末端连接的接头肽。 p75NTR-ECD的氨基酸序列如SEQ ID NO:1所示,核苷酸序列如SEQ ID NO:2所示。人IL-33的氨基酸序列如SEQ ID NO:1所示。核苷酸序列如SEQ ID NO.:3所示。 4.本发明克服了用于预防和治疗阿尔茨海默氏病的p75NTR-ECD或融合蛋白p75NTR-ECD-FC的缺陷。另外,IL-33和p75NTR-ECD的功能结合在一起,预防和治疗阿尔茨海默氏病的生物学活性显着提高。

著录项

  • 公开/公告号US2019300596A1

    专利类型

  • 公开/公告日2019-10-03

    原文格式PDF

  • 申请/专利权人 SHENZHEN MAIDIKE BIOTECHNOLOGY CO. LTD.;

    申请/专利号US201716304606

  • 发明设计人 JUNBO MAI;

    申请日2017-07-13

  • 分类号C07K14/705;A61P25/28;C07K14/54;

  • 国家 US

  • 入库时间 2022-08-21 12:09:11

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号